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Abstract
Since brain tissue is not readily accessible, a new focus in search of biomarkers for schizophrenia is blood-based expression
profiling of non-protein coding genes such as microRNAs (miRNAs), which regulate gene expression by inhibiting the
translation of messenger RNAs. This study aimed to identify potential miRNA signature for schizophrenia by comparing
genome-wide miRNA expression profiles in patients with schizophrenia vs. healthy controls. A genome-wide miRNA
expression profiling was performed using a Taqman array of 365 human miRNAs in the mononuclear leukocytes of a
learning set of 30 cases and 30 controls. The discriminating performance of potential biomarkers was validated in an
independent testing set of 60 cases and 30 controls. The expression levels of the miRNA signature were then evaluated for
their correlation with the patients’ clinical symptoms, neurocognitive performances, and neurophysiological functions. A
seven-miRNA signature (hsa-miR-34a, miR-449a, miR-564, miR-432, miR-548d, miR-572 and miR-652) was derived from a
supervised classification with internal cross-validation, with an area under the curve (AUC) of receiver operating
characteristics of 93%. The putative signature was then validated in the testing set, with an AUC of 85%. Among these
miRNAs, miR-34a was differentially expressed between cases and controls in both the learning (P=0.005) and the testing set
(P=0.002). These miRNAs were differentially correlated with patients’ negative symptoms, neurocognitive performance
scores, and event-related potentials. The results indicated that the mononuclear leukocyte-based miRNA profiling is a
feasible way to identify biomarkers for schizophrenia, and the seven-miRNA signature warrants further investigation.
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Introduction
Schizophrenia is a common and often disabling mental illness
characterized not only by a varied group of clinical symptoms [1]
but also wide-ranging deficits in neurocognitive and neurophysio-
logical functions [2–4]. Although the underlying pathophysiology of
schizophrenia remains not well understood, dysregulations of its
susceptibility genes are likely to converge functionally upon illness
risk [5], which may manifest as certain endophenotypes, such as
abnormalities in sustained attention, executive function, or event-
related potentials [6–7]. Biomarkers that reflect these dysregulations
for schizophrenia have the potential to substantially improve the
clinical management of the disorder and even revolutionize its drug
development approaches [8–9]. Since brain tissue is not readily
accessible for investigation, blood-based expression profiling is
increasingly being undertaken to search for potential biomarkers for
schizophrenia [10–13].
The rationale of searching for peripheral blood-based gene
expression aberration for schizophrenia is two-folded. First, consti-
tutional variants of susceptibility genes exhibited only limited
association with schizophrenia as revealed in systematic meta-
analyses of genome-wide association studies [14]. Hence, an
alternative way is to look for measures that can reflect the combined
effect of genetic predisposition and environmental exposure, such as
aberrations of gene expression. Second, the central nervous system
(CNS) may exert its influence on the gene expression of peripheral
lymphocytes via cytokines, neurotransmitters, or hormones [15–16],
which may explain the comparable gene expression levels between
the peripheral blood and some CNS tissues [11–12], as well as the
alterations in the dopamine transporter in the lymphocytes of
psychotic patients [17]. Furthermore, the peripheral expression levels
of some dysregulated genes were also found to be correlated with
certain clinical symptoms and neurocognitive functions in patients
with schizophrenia [18].
However, most of previous blood-based gene expression studies
on schizophrenia [10–13] were limited to the expression of
protein-coding genes, in which an enormous number of messenger
RNAs (mRNAs) have to be examined using microarray platforms.
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to schizophrenia and most of them were not replicated in the other
studies [19]. Growing attention has been focused on the regulatory
roles of microRNAs (miRNAs), which regulate gene expression by
inhibiting the translation of mRNAs [20], as potential biomarkers
for schizophrenia [21–25]. Since each miRNA can regulate the
expressions of hundred of target genes, the number of discrimi-
nating miRNA markers would be much less than that of mRNAs.
Indeed, in some preliminary array-based miRNA profiling studies,
the expressions of less than thirty miRNAs were found to be
altered in the post-mortem brains of schizophrenia patients [26–29].
As exemplified by the parallel changes in the levels of certain
mRNAs between the CNS and peripheral blood [15–17], it is
plausible that some expression aberrations of miRNAs might also
be detectable in the peripheral mononuclear leukocytes.
In this study, we aimed to identify miRNAs that might be useful
as biomarkers for schizophrenia in a two-stage manner. We first
examined array-based miRNA profiles in peripheral mononuclear
leukocytes from a learning set of schizophrenia patients and healthy
controls, and then the discriminating performance of candidate
miRNAs was validated in an independent testing set of cases and
controls. The expression levelsof the miRNA signature werefurther
evaluated for their correlation with the patients’ clinical symptoms,
neurocognitive performances, and neurophysiological functions.
Possible functions and biological mechanisms implicated in the
target genes regulated by the miRNAs were then explored using
database prediction.
Results
There were no differences in age or sex between patients with
schizophrenia and healthy controls, whereas the patients’ education
levels were lower than those of the controls in both the learning and
testing sets, and the patients’ smoking prevalence was higher than
controls’ in the testing set (Table S1). Patients’ mean age at onset
was 23.7 for the learning set and 24.6 years for the testing set.
Out of the 365 miRNAs assayed using the Taqman Low
Density Array (TLDA) in the learning set of 30 schizophrenia
patients and 30 controls, the expression levels of 221 (60.5%) were
detectable in the peripheral mononuclear leukocytes of $30% of
the samples in either the schizophrenia patients or the controls.
Among them, there were eight miRNAs that were differentially
expressed between schizophrenia patients and healthy controls in
the learning set based on a criterion of P,0.05 in the Wilcoxon
rank-sum test (Figure 1). From these a seven-miRNA signature
(miR-34a, miR-449a, miR-564, miR-432, miR-548d, miR-572
and miR-652) was identified using stepwise logistic regression
analysis, with a fold-change ranging from 21.4 to 2.5 (Table 1).
Among the seven, four in the human database miRNAMap [30]
and one in a mouse model [31] were reported to have detectable
expressions in the brain, whereas the remaining two did not. The
pattern of expression gradients of these seven miRNAs can be
distinguished between the two groups, as shown in Figure 2a.
As an initial check for the utility of the 7-miRNA signature, the
prediction accuracy at an arbitrary cut-off point in the learning set
was evaluated using two different methods. For the logistic
regression analysis with leave-one-out cross-validation, the raw
accuracy rate was 80%, and the adjusted accuracy rate, i.e., with
adjustment for potential confounders such as age, gender,
education and tobacco smoking, was elevated to 83.1%. When
the Support Vector Machine (SVM) [32] was used for the
evaluation, the raw and adjusted accuracy rate was 84.3% and
82.1%, respectively. Meanwhile, the global performance of the
seven-miRNA signature in distinguishing the schizophrenia
patients from the normal controls, the area under the curve
(AUC) of receiver operative characteristics, was estimated to be
0.93 for the learning set, regardless of the adjustment for
confounders (Figure 3). When the disease status was permuted
for the seven-miRNA signature, none of the permuted AUCs
exceeded the observed value of 0.93, i.e., a significance level of
,0.0001 regardless of the unadjusted or adjusted model (data not
shown). When the seven miRNAs were randomly selected from
the pool of 221 miRNAs for 100,000 times, the mean of these
AUCs were 0.69 (SD=0.06) for the model without adjustment
and 0.737 (SD=0.05) for the model with adjustment for
confounders. None of the unadjusted model (P,0.00001) and
one of the adjusted model (P=0.00001) had an AUC greater than
the observed. The histograms of the permuted AUCs for these two
models are displayed in Figure S1. When the number of miRNAs
selected ranged from 3 to 9, the mean AUC increased slightly but
remained less than 0.78 (see Table S2 for the summary of the
permutations).
The discriminating accuracy of seven-miRNA signature was
then evaluated in an independent testing set of 60 schizophrenia
patients and 30 controls using quantitative reverse transcription-
polymerase chain reaction (qRT-PCR). The differential expression
gradients of the 7-miRNA signature in the testing set is illustrated
in Figure 2b. The raw and adjusted accuracy rate for the logistic
regression analysis with leave-one-out cross-validation was 73.3%
and 80.0%, respectively, and the corresponding figure for the
SVM was 76.2% and 78.3%, respectively. In terms of the global
performance, the AUC was estimated to be 0.77 (without
adjustment) and 0.85 (with adjustment), respectively (Figure 3).
The permutation-based significance level for the testing set was of
,0.0001, regardless of the unadjusted or adjusted model.
Regarding the individual miRNA expression level of the seven
miRNAs, the differential expression in hsa-miR-34a between the
cases and controls reached statistical significance in both the
learning set (P=0.005) and the testing set (P=0.002) (Figure 4).
The distributions of subjects’ clinical symptoms rated in the
Positive and Negative Symptom Scale (PANSS) [33], neurocog-
nitive performances using the Continuous Performance Test
(CPT) [34–35] and the Wisconsin Card Sorting Test (WCST)
[36], and neurophysiological functions measured as P50 suppres-
sion in auditory event-related potentials (ERPs) [37] and
mismatched negativity (MMN) [38] are shown in Table S3. For
the pooled sample of schizophrenia patients, some scores on the
PANSS, CPT, WCST, and MMN were correlated with the
expression levels of certain miRNAs, whereas none of the P50
suppression indexes showed such a correlation (Table 2).
For the analyses of the predicted miRNA-target genes, 621
genes for three miRNAs (hsa-miR-34a, hsa-miR-449a, and has-
miR-432) were obtained using MAMI [39] and 684 genes for two
miRNAs (hsa-miR-34a and hsa-miR-449a) were obtained using
TargetCombo [40] (see Table S4 for the setting in each method
and the results for each miRNA). Since more information was
available for the predicted target genes using MAMI, we further
examined whether there were common target genes among the
three miRNAs. The results revealed that there were 128 miRNA-
target genes shared between hsa-miR-34a and hsa-miR-449a, 1
target gene shared between hsa-miR-34a and hsa-miR-432, and 1
target gene shared between hsa-miR-432 and hsa-miR-449a (see
Table S5 for the complete list).
For each set of predicted target genes, their functions and
putative pathways were explored using the software Ingenuity
Pathways Analysis (IPA), version 8 (IngenuityH Systems), with 619
(99.7%) of MAMI-based target genes and 520 (84%) of Target-
Combo-based target genes were successfully mapped. The most
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analysis was nervous system development and function for both sets
of predicted genes (P of Fisher’sexacttest=0.000002 for the MAMI
and 0.0000013 for the TargetCombo). Since the MAMI-based set
covered more miRNAs and predicted target genes, we further
explored its canonical biological pathways, with the most significant
pathways being cyclin dependent kinase 5 (Cdk5), Notch signaling,
and dopamine receptor signaling pathways (Figure S2). After
correction for multiple testing using the false discovery rate method,
both Cdk5 and Notch signaling pathways remained significantly
associated with these genes (p,0.001).
Discussion
Our two-staged search for miRNAs with aberrant levels in
blood mononuclear leukocytes revealed a combination of seven
miRNA expression alterations to have robustly high discriminating
accuracy for schizophrenia. The differential correlation of these
miRNAs with patients’ negative symptoms, neurocognitive
performance scores, and event-related potentials further imply
that the aberration of certain functions in the brain might result in
alteration of molecular abnormalities in peripheral lymphocytes
[15–16,41]. These changes in the post-transcriptional regulatory
environment of lymphocytes in patients with schizophrenia not
only have implications for the pathophysiology of the disorder
[21,28] but also provide as empirical source of non-invasive
biomarkers for schizophrenia.
The use of seven miRNAs as predictors for the disease status has
in general more stable prediction accuracy than using a single
predictor [42]. Using hsa-miR-34a as an example, which was the
mostdifferentiallyexpressedmiRNAinthemononuclear leukocytes
of patients in both the learning and the testing set, its sole prediction
accuracy was only around 50% to 60% (data not shown). Since
schizophrenia is a complex neurodevelopmental disorder with a
varied group of clinical symptoms, the combined alterations of
miRNA expressionin the lymphocytesmight result from the stresses
from different brain regions [15,41,43]. This is further supported by
the differential correlations of these miRNAs with patients’ clinical
symptoms and neurocognitive or neurophysiologic measures.
Among the seven miRNAs, the expression level of hsa-miR-34a
was found to be altered in the prefrontal cortex of patients with
schizophrenia [44]. The expression levels of miR-34a on the
hippocampus of rats were also found to be altered in response to
mood stabilizers [45]. In cultured cell lines, mood stabilizers could
both lower the levels of miR-34a and elevate the levels of GRM7,
a confirmed target gene regulated by miR-34a as well as a
candidate gene for schizophrenia identified in recent association
studies [46]. It should be noted that miR-34a was also significantly
up-regulated in the blood mononuclear cells of patients with
Alzheimer’s disease [47]. Thus, the role of miR-34a over-
expression in the pathophysiology of schizophrenia warrants
further investigation. Three other miRNAs have also been
implicated in neuropsychiatric disorders or neurodevelopment,
e.g., miR-432 with autism in human cerebella cortex [48], miR-
449 with Alzheimer’s disease in cerebrospinal fluid [49], and miR-
652 with embryogenesis in the mouse brain and spinal cord [31].
Despite the fact that we do not know whether the aberrant
expression of the seven miRNAs were also present in the patients’
CNS, the majority of them are detectable in the brain according to
the literature [30–31]. In addition, some of the seven miRNAs
identified in this study were correlated with negative symptoms,
neurocognitive dysfunction, and MMN in ERPs in patients with
schizophrenia. It is worthwhile to note that miR-449a significantly
correlated with most features of the WCST, implying that miR-
449a might be sensitive to the executive function activity in the
brain. It is plausible that the CNS may exert its influence on the
gene expression of peripheral lymphocytes via cytokines, neuro-
transmitters, or hormones [15–16]. Thus, it warrants further
investigation regarding which molecules are involved in such
influence on peripheral lymphocytes.
Taken together, the aberrant expression of the miRNAs in the
peripheral lymphocytes or monocytes of schizophrenia patients could,
to some extent, reflect the corresponding dysfunction in the brain,
which is compatible with the predicted canonical pathways for these
miRNAs, including Cdk5, Notch signaling, and dopamine receptor
signaling pathways. Although our prediction analyses of miRNA-
target genes and pathways were based on in-silico simulation, some of
the miRNA-target genes have been validated in previous studies [50].
Hence, our results are compatible with the implication of the
dysregulation of these genes and pathways in the pathophysiology of
schizophrenia [5,51–52]. In future work, the miRNA-target genes
need to be validated in our samples by evaluating the correlation
Figure 1. miRNA expression profiling of 221 miRNAs in the learning set of 30 schizophrenia patients and 30 controls. The heatmaps
of individual miRNAs for each group of subjects were presented as the averaged rank-sum of the normalized threshold cycle number, with less
numbers indicating higher expression levels. The eight differentially expressed miRNAs were marked by an asterisk.
doi:10.1371/journal.pone.0021635.g001
Table 1. The seven microRNA-signature derived from the learning set (30 patients with schizophrenia and 30 healthy controls).
miRNA name Chromosomal region Location P
a value Fold change Expression levels in the brain
hsa-miR-34a 1p36.23 Intergenic 0.005 2.5 Moderate
b
hsa-miR-449a 5q11.2 Intron 0.007 1.9 Low
b
hsa-miR-564 3p21.31 39 UTR 0.015 2.4 NA
hsa-miR-432 14q32.31 Intergenic 0.022 21.4 High
b
hsa-miR-548d 8q24.13 Intron 0.036 1.4 NA
hsa-miR-572 4p15.33 Intergenic 0.038 2.1 Moderate
b
hsa-miR-652 Xq22.3 Intron 0.049 2.4 Moderate
c
abased on the Wilcoxon rank-sum test.
bhttp://mirnamap.mbc.nctu.edu.tw/.
cmiR-652 was expressed in the brain and spinal cord during embryonic stages followed by a gradual decrease after birth in a mouse model.
doi:10.1371/journal.pone.0021635.t001
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qRT-PCR method, and the miRNA-target interactions need to be
confirmed using exogenous (e.g., to over-express certain miRNAs in
neural cell lines and then examine the protein expression level of the
target genes) or endogenous (e.g., conducting the manipulation of
miRNAs in physiological conditions) miRNA experiments [50].
It is intriguing to note that two of the seven miRNAs, miR-34a
and miR-449a, share the same seed sequence and the direction
Figure 3. The area under the receiver operative characteristics
curve of the seven-miRNA signature in the learning (in blue
color) and testing (in green color) sets, respectively, without (in
solid line) or with (in dotted line) adjustment for age, gender,
education, and tobacco smoking.
doi:10.1371/journal.pone.0021635.g003
Figure 4. The relations in has-miR-34a miRNA expression levels
between two platforms of miRNA quantification, the array-
based TLDA vs. individual quantification using quantitative
RT-PCR. The differential expressions in hsa-miR-34a between the cases
and controls in both the learning set (P=0.005) and the testing set
(P=0.002).
doi:10.1371/journal.pone.0021635.g004
Figure 2. A comparison of: (A) the TLDA-based miRNA expression levels between the schizophrenia patients (n=30) and the
controls (n=30) for the seven miRNAs; and (B) quantitative RT-PCR-based miRNA expression levels between the schizophrenia
patients (n=60) and the controls (n=30) for the same seven miRNAs. The red, black, and green hues denote relatively high, intermediate,
and low expression levels. To emphasize the rank-sum property of the Wilcoxon test, all the expression levels of miRNA were converted to relative
expression ranks within each miRNA. Ranks for each miRNA were sorted separately for the control group and disease group before they were placed
side-by-side for easier comparison between the two groups and across all putatively informative miRNAs.
doi:10.1371/journal.pone.0021635.g002
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Furthermore, they also shared similar miRNA-target genes as
predicted using MAMI (Table S5). Among them, some have been
confirmed in previous studies, such as delta-like 1 (DLL1) and
jagged 1 (JAG1) genes, which are involved in NOTCH signaling
pathway [53], B-cell CLL/lymphoma 2 (BCL1), which impacts
outcomes after sever traumatic brain injury [54], and mitogen-
activated protein kinase kinase 1 (MAP2K1), which is aberrantly
expressed in the brain of suicide subjects [55]. Another intriguing
finding is that despite the close alignment of miR-449b to miR-
449a, the former was not selected as a predictive biomarker in this
study. Previous studies indicated that the expression levels of miR-
449a exceed those of miR-449b in all the systems analyzed [56].
Consistent with this, 70% of the 60 subjects of the learning set in
this study had higher expression levels of the miR-449a than
miRNA-449b in mononuclear leukocytes, which might explain the
lack of association of miR-449b expression level with schizophre-
nia in this study.
Our results should be interpreted with several limitations in
mind. First, since all the schizophrenia patients were receiving
combinations of medications, the influences of psychopharmaco-
logic medications on miRNA expression levels were not accounted
for in this study. Second, despite our matching in age and gender,
there were substantial differences between the patients and
controls in educational level. Nevertheless, it is not known whether
educational level has much influence on the expression levels of
miRNA. Finally, subgroup analysis based on patients’ endophe-
notypic characteristics was not conducted in this study due to
limited sample size.
Our findings demonstrate the potential utility of a mononuclear
leukocyte-based miRNA signature as biomarkers for schizophre-
nia, which could help elucidate the etiology of schizophrenia as
well as proffer better treatments. The results of correlation
between clinical symptoms and miRNA expression levels suggest
that lymphocyte could reflect the metabolism of brain cells, and
may be exploited as a neural and possible genetic probe in studies
of psychiatric disorders [15–16]. Since a specific miRNA might be
involved in coordinated regulation of protein expression in
functional networks [24], this kind of biomarkers might contribute
to new development of target therapeutic intervention in near
future [8]. We conclude that genome-wide miRNA profiling is a
feasible way to identify potential biomarkers for schizophrenia,
and the seven-miRNA signature warrants further investigation.
Materials and Methods
Participants
From December 2007 to September 2009, we enrolled 90
patients who met the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition [57] criteria for schizophrenia at
Table 2. The Spearman correlation coefficients between the seven miRNA signature
a and the clinical symptoms of schizophrenia
patients from both the learning and testing sets. (Only those with P,0.05 are shown here.)
1234567
Variable hsa-miR-34a hsa-miR-449a hsa-miR-564 hsa-miR-432 hsa-miR-548d hsa-miR-572 hsa-miR-652
PANSS (n=83)
Negative scale 0.25
Continuous Performance
Test (n=78)
Undegraded d92 0.25 20.27
Undegraded false alarm
rate
0.23 0.29*
Degraded ln ? 0.24 0.28*
Degraded false alarm
rate
20.31*
Wisconsin Card Sorting
Test (n=78)
Total errors 0.28*
Perseverative responses 0.22
Perseverative errors 0.21
Non-perseverative
errors
0.29*
Categories achieved 20.31** 0.24*
Conceptual level
response
20.29*
Mismatch Negativity
(n=70)
Cz 20.31
FCz 20.28
aThe 2DCt value of each miRNA was standardized (mean=0, SD=1) in the learning and testing sets, respectively.
bScores on the PANSS, MMN, and P50 were adjusted for age, gender, and educational level.
*P,0.01;
**P,0.006.
doi:10.1371/journal.pone.0021635.t002
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healthy controls with a frequency matching in age and sex from a
pool of staff, graduate students, and community volunteers. The
sample was randomly separated into a learning set (30 cases and
30 controls) and a testing set (60 cases and 30 controls). Individuals
with severe neurological abnormalities, emotional disorders,
mental retardation, or prominent substance abuse problems were
excluded. Each participant provided written informed consent
after being given a complete description of the study. The study
was approved by the institutional review board of National
Taiwan University Hospital.
Clinical assessments
All the patients were interviewed using the Chinese adaptation
[34] of the Diagnostic Interview for Genetic Studies (DIGS) [58]
by well-trained research assistants with background in psychology
or nursing. Best estimate psychiatric diagnosis was determined
independently by two psychiatrists using all available information,
including the DIGS, hospital records, and the interviewer’s notes.
If both disagreed about a diagnosis, a third one was sought and a
consensus in diagnosis was reached after discussion [59].
Each patient’s clinical symptoms were rated by a research
psychiatrist using the PANSS [33]. The translation of the PANSS
into Chinese was described elsewhere [60] and the instrument was
shown to have good inter-rater reliabilities (intraclass correlation
ranging from 0.64 to 0.96) in a subsequent study [61].
Neurocognitive assessments
Each participant’s sustained attention was assessed using a CPT
machine from Sunrise Systems, v.2.20 (Pembroke, MA, USA),
with the procedure and reliability data being described in more
detail elsewhere [34–35]. Briefly, numbers from 0 to 9 were
randomly presented for 50 msec each, at a rate of one per second.
Each subject undertook two CPT sessions: the undegraded 1–9
tasks and 25% degraded 1–9 tasks. Two signal-detection indexes
of performance on the test, sensitivity (d9) and response criterion
(ln b), were derived from the hit rate and false-alarm rate.
Sensitivity measures an individual’s ability to discriminate target
stimuli from nontarget stimuli, whereas response criterion assesses
the amount of perceptual evidence an individual requires prior to
making a decision to respond to a stimulus as a signal.
Then each participant’s executive function was assessed using a
computerized version of the WCST [36]. Subjects were required
to match response cards to the four stimulus cards along one of
three dimensions (color, form, or number) by pressing one of the 1
to 4 number keys on the computer keyboard. Subjects were not
informed of the correct sorting principle, nor were they told when
the principle would shift during the test, but they were given
feedback on the screen after each trial. Eight performance indices
were used for subsequent analyses: Total Errors, Nonperseverative
Errors, Perseverative Errors, Perseverative Responses, Categories
Achieved, Trials to Complete First Category, Conceptual Level
Response, and Failure to Maintain Set [62].
Electrophysiological assessments
Each participant was assessed for auditory ERPs using P50
suppression [37] and MMN [38]. Participants were in a sound-
attenuating, electrically shielded booth, and did not smoke for at
least 60 min before the testing. They were seated in a comfortable
recliner and instructed to relax with their eyes open and to focus
on a fixation point (P50 session) or the video monitor (MMN
session). The stimuli were generated and data were recorded using
Neuroscan (Neuroscan, El Paso, Texas) STIM and ACQUIRE
system. Electrodes were used at up to 40 recording sites (according
to International 10–20 system) utilizing an electrode cap. Auditory
stimuli were presented to subjects binaurally via foam insert
earphones. Electroencephalography and stimulus markers were
recorded continuously, while subjects were instructed to minimize
eye movements and muscle artifact during the recording.
RNA extraction and miRNA quantification
Approximately 10 ml of whole blood were collected and
processed within 3 hours. Mononuclear leukocytes were separated
via centrifuging with Ficoll-Paque PLUS (GE Healthcare). Since
lymphocytes, monocytes, and platelets were not dense enough to
penetrate into the Ficoll-Paque PLUS layer, this resulted in a
concentrated band at the interface between the original blood
sample and the Ficoll-Paque PLUS. This banding enabled the
lymphocytes to be recovered with high yield in a small volume
with little mixing with the Ficoll-Paque PLUS medium. Subse-
quent washing and centrifugation of the harvested cells removed
platelets, plasma, and any contaminating Ficoll-Paque PLUS. The
resulting cell suspension then contained highly purified, viable
mononuclear leukocytes (95%65%), in which the majority were
lymphocytes (60%620%). The suspension of mononuclear
leukocytes might contain microviscles. However, the amount
might be negligible since the majority of the peripheral blood
microvesicles were platelet-derived [63], which were presumably
washed out by the washing and centrifugation step.
Then the total RNA of these mononuclear leukocytes was
extracted using TRIzol reagent (Invitrogen). The qualities of RNA
extracts were found to be good, i.e., RNA integrity number
(RIN).8. In the learning set, the expression of 365 human
miRNAs and endogenous control RNU48 small nuclear RNA
were assayed using Multiplex RT and TaqManH Low Density
Array (TLDA) Human MicroRNA Panel v1.0 and 7900 real-time
RT PCR System (Applied Biosystems). A total of 800 ng RNAs
were used for each array.
The corresponding cDNAs were made using TaqMan Micro-
RNA reverse transcription (RT) reagents and specific primers for
the miRNAs (Applied Biosystems). The amount of RNAs used for
RT was 2 ng. qRT-PCR of miRNAs was performed using
Taqman MicroRNA assays and 7900 real-time RT-PCR system
(Applied Biosystems) with RNU48 as an endogenous control. A
total of 0.8 ng RT products were used for qRT-PCR. All assays
were performed in duplicate.
To confirm the comparability of TLDA-based genome-wide
profiling with individual quantifications, we randomly chose 10
patients and 10 controls from the learning set and further quantified
these subjects’ expression levels of five miRNAs (has-miR 34a, miR-
432, miR-548d, miR-659 and miR-185) using quantitative RT-
PCR. Among the miRNAs detectable using TLDA, there was a
significant correlation (r=0.83, P,0.0001) in the expression levels
of miRNA between the two methods (Figure S3).
Statistical analyses
The expression level of each miRNA was quantified by its
normalized threshold cycle number DCt, in which DCt=[C t
(miRNA)]2[Ct (U48)], and the relative expression level was
calculated as 2
2(DCt), which is commonly used in genomewide
profiling studies of miRNAs [64]. Only those miRNAs detectable
in the peripheral mononuclear leukocytes of $30% of the samples
of either the schizophrenia patients or the controls were
subsequently analyzed. To select differentially expressed miRNAs
for further classification, a two-sided Wilcoxon rank-sum test was
used to compare the two groups’ expression levels with a threshold
P value of 0.05. Stepwise logistic regression analyses were then
used to select a miRNA signature with the maximum acceptable a
MicroRNA Expression Aberration and Schizophrenia
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21635limit for adding a variable being 0.1 and the minimum acceptable
a limit for removing a variable being 0.15.
We used two different methods in a supervised classification
with leave-one-out cross-validation [65] to assess the prediction
accuracy of the miRNA-signature in the learning set: logistic
regression and SVM. Logistic regression allows for non-linear
discriminant analysis and is more robust against departures from
normality than discriminant analysis, whereas SVM is particularly
useful for high-dimensional classification problems [32]. A
supervised classification with leave-one-out cross-validation can
provide a nearly unbiased estimate of the true error rate [65]. In
these analyses, a confounder score method [66] was used to adjust
for age, gender, education, and tobacco smoking. To assess the
robustness of the predictive utility of the seven-miRNA signature,
two kinds of permutations were conducted. First, keeping the
seven-miRNA signature, we randomly permuted the disease status
among the learning set and the testing set, respectively, for 10,000
times and the number of the permuted AUC exceeding the
observed AUC was counted as permuted significance level.
Second, keeping the disease status of the learning set of subjects,
a certain number of miRNAs, ranging from 3 to 9, were randomly
selected from the pool of 221 miRNAs and the corresponding
AUC for the model without and with control of potential
confounders, respectively, were calculated.
To help visualize the differential expression pattern, we adopted
the method of matrix visualization using the software program
Generalized Association Plots [67] to compare the miRNA
expression levels between cases and controls.
For correlation analysis, either a Pearson (between array-based
expression level and qRT-PCR expression level) or a Spearman
(between the expression levels of miRNAs and scores on the
clinical symptoms, neurocognitive tests, and ERPs) correlation
coefficient was used. The expression level of individual miRNA
was standardized by subtraction from the group mean followed by
division by the standard deviation within each platform. Then the
standardized expression levels of miRNAs from two platforms
were pooled.
Target genes prediction and functional profiling
The potential target genes regulated by the miRNAs were
predicted using two different methods: the MAMI MicroRNA
Meta-Predictor [39] and TargetCombo [40]. These two methods
incorporate several popular prediction algorithms including miRs,
Targets, microT [68], PicTar [69], TargetScanS [70], miRTarget
[71], and miRanda [72]. For the predicted target genes, their
functions and putative pathways were explored using the IPA version
8( I n g e n u i t y H Systems). Fisher’s exact test was used to calculate the
significance of the association between the data set and the biological
function or canonical pathway. The false discovery rate procedure
were used to control for the multiple hypothesis testing [73].
Supporting Information
Figure S1 The histogram of the AUCs in 100,000 permutations
of random selection of seven miRNAs from the pool of 221
miRNAs for (a) the model without adjustment and (b) the model
with adjustment for confounders (age, gender, education, and
tobacco smoking).
(TIF)
Figure S2 The canonical pathways revealed by means of using
the software Ingenuity Pathways Analysis to be significantly
(P,0.005) associated with the 619 miRNA-target genes predicted
using MAMI. The pathways that remained significantly associated
with the predicted target genes after corrections for multiple
testing using the false discovery rate (p,0.001) were marked by an
asterisk.
(TIF)
Figure S3 The relations in the five miRNAs (has-miR 34a, miR-
432, miR-548d, miR-659 and miR-185) expression levels between
two platforms of miRNA quantification, the array-based TLDA
vs. individual quantification using quantitative RT-PCR in the
learning set of 10 schizophrenia patients and 10 controls. The
Pearson correlation in detectable miRNA expression levels
between the two methods was r=0.83 (P,0.0001).
(TIF)
Table S1 Demographic characteristics of schizophrenia patients
and healthy controls in the learning set and testing set,
respectively.
(DOC)
Table S2 Summary statistics of the area under the curve (AUC)
of receiver operating characteristics of 100,000 permutations of
random selection of a certain number of miRNAs from the pool of
221 miRNAs in the learning set of 30 schizophrenia patients and
30 controls.
(DOC)
Table S3 Measures on clinical, neurocognitive, and auditory
event related potentials in schizophrenia patients and normal
controls.
(DOC)
Table S4 Summary of miRNA-target prediction using two
different methods: the MAMI MicroRNA Meta-Predictor and
TargetCombo.
(DOC)
Table S5 The common miRNA-target genes that were predict-
ed by MAMI MicroRNA Meta-Predictor shared by different
miRNAs.
(DOC)
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